Clinical Trials Sponsored by Action, France

Total 6553 results

Sciton

Completed

Safety and Efficacy of Broad Band Light In Motion Treatment

Pigmentation

United States
Sciton

Completed

Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions

Dermatology/Skin - Other

United States
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Actelion

Completed

OPsumit USers Registry (OPUS)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Actelion

Completed

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction (MELODY-1)

Pulmonary Hypertension

United States, Austria, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Spain, Switzerland
Actelion

Terminated

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension (VISION)

Pulmonary Hypertension

United States
Actelion

Terminated

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile Infection

United States, Belgium, Canada, Czechia, Hungary, Italy, Poland, Romania, Spain
Actelion

Completed

Bosentan in Digital Ulcers (RAPIDS 2 OL)

Digital Ulcers

France, United Kingdom, United States, Austria, Canada, Germany, Italy, Switzerland
Actelion

Completed

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Gaucher Disease Type 1

United States, Taiwan, Canada, Spain, Australia, France, Brazil, Hungary, Czechia, Germany, Italy, Netherlands, United Kingdom
Actelion

Completed

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States (OrPHeUS)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Actelion

Terminated

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Chronic Graft Versus Host Disease

United States
Actelion

Completed

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (TRANSIT-1)

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (GRIPHON)

Pulmonary Arterial Hypertension

United States, Canada, Colombia, Malaysia, Austria, Israel, Ukraine, Germany, Australia, China, Argentina, Mexico, Spain, Hungary, Belarus, Belgium, Chile, Czechia, Denmark, France, Greece, India, Ireland, Italy, Korea, Republic of, Nethe... and more
Actelion

Completed

Bosentan in Children With Pulmonary Arterial Hypertension Extension Study (FUTURE 2)

Pulmonary Arterial Hypertension

United States, France, Netherlands, Italy, Germany, Switzerland, United Kingdom
Actelion

Completed

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Healthy Subjects

Germany
Actelion

Completed

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Germany, France, United Kingdom
Actelion

Terminated

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Glioblastoma

United States
Actelion

Withdrawn

Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension (LONGACT)

Pulmonary Arterial Hypertension
Actelion

Completed

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15 Ext)

Pulmonary Arterial Hypertension

United States, Germany, Austria
Actelion

Completed

Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects

Healthy

United Kingdom
Actelion

Completed

Open-label Study With Bosentan in Interstitial Lung Disease (BUILD 2 OL)

Interstitial Lung Disease | Scleroderma

United States, Korea, Republic of, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Canada, Italy, Sweden
Actelion

Completed

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Melanoma

Australia
Actelion

Completed

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-1)

Systemic Sclerosis | Ulcers

Canada, United States, Belarus, Hungary, Croatia, Australia, Denmark, Ukraine, Bulgaria, Chile, Colombia, Czech Republic, Finland, Germany, India, Italy, Poland, Russian Federation
Actelion

Withdrawn

Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (MUSIC OL)

Idiopathic Pulmonary Fibrosis
Actelion

Completed

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Pharmacokinetics | Tolerability | Safety | Cardiodynamics

United States
Actelion

Completed

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

Bioequivalence

Netherlands
Actelion

Completed

Miglustat in Cystic Fibrosis

Cystic Fibrosis

Belgium
Actelion

Completed

Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection

Clostridium Difficile Infection

Croatia
Actelion

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects

Safety and Tolerability

United Kingdom
Actelion

Completed

Combination Therapy in Pulmonary Arterial Hypertension (COMPASS 3)

Pulmonary Arterial Hypertension

United States
Actelion

Terminated

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Pulmonary Hypertension

United States
Actelion

Completed

Epoprostenol for Injection in Pulmonary Arterial Hypertension (EPITOME-1)

Pulmonary Arterial Hypertension

United States
Actelion

Terminated

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) (DETECT)

Systemic Sclerosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Canada, Spain, Hungary, Switzerland, Turkey, Germany, Austria, Bosnia and Herzegovina, Brazil, China, Czech Republic, Netherlands, Norway, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, United Kingdom
Actelion

Completed

Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Canada, Australia, Germany, United States, Italy, United Kingdom, Austria, Belgium, Czech Republic, France, Netherlands, Poland, Spain
Actelion

Withdrawn

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

Scleroderma, Systemic | Pulmonary Fibrosis

United States, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Italy, Sweden
Actelion

Completed

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
Actelion

Completed

ACT-128800 in Psoriasis

Plaque Psoriasis

Germany, Hungary, Austria, France, Serbia
Actelion

Recruiting

A Study of Macitentan in Children Below 2 Years of Age

Arterial Hypertension, Pulmonary

Poland, Germany
Actelion

Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (UNISUS)

Pulmonary Arterial Hypertension

Belgium, United States, Italy, Canada, Taiwan, Greece, China, Korea, Republic of, Germany, Israel, Austria, Russian Federation, Australia, Thailand, United Kingdom, Brazil, Malaysia, Spain, Ukraine, Bulgaria, Colombia, Mexico, Turkey, Vietna... and more
Actelion

Recruiting

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (TOMORROW)

Pulmonary Arterial Hypertension

United States, Korea, Republic of, Spain, Malaysia, China, Hungary, Mexico, Poland, Australia, Austria, Brazil, Canada, Colombia, France, Israel, Philippines, Portugal, Russian Federation, South Africa, Thailand, Ukraine, Vietnam, F...
Actelion

Active, not recruiting

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (A DUE)

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

United States, Japan, Taiwan, Turkey, Canada, China, Germany, Spain, Italy, Malaysia, Hungary, Russian Federation, Brazil, Australia, Bulgaria, Czechia, Mexico, Poland, South Africa
Actelion

Completed

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT)

Multiple Sclerosis

United States, Spain, Hungary, Israel, Portugal, Germany, Russian Federation, Belarus, Poland, Serbia, Latvia, Turkey, Croatia, Canada, Czechia, Bulgaria, Bosnia and Herzegovina, Finland, France, Georgia, Greece, Italy, Lithuania, Mexico and more
Actelion

Terminated

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (RESTORE)

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, Israel, Singapore, United States, Russian Federation, Brazil, Netherlands, Malaysia, Saudi Arabia, United Kingdom, Hong Kong, France, United Arab Emirates, Argentina
Actelion

Completed

ACT-293987 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Poland, Ukraine, United Kingdom, China, Germany, Taiwan, France, Spain, Switzerland, Argentina, Belarus, Belgium, Colombia, Israel, India, Malaysia, Romania, Serbia, Canada, Australia, Netherlands, Denmark, Greece, Korea,... and more
Actelion

Terminated

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment (SELECT)

Chronic Thromboembolic Pulmonary Hypertension

United States, Taiwan, Belgium, Canada, Korea, Republic of, United Kingdom, Turkey, Poland, Austria, Portugal, Spain, Italy, Switzerland, China, Malaysia, Netherlands, Australia, Thailand, Hungary, Brazil, Bulgaria, Czechia, Germany, ... and more
Actelion

Completed

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE)

Heart Failure With Preserved Ejection Fraction

United States, Spain, United Kingdom, Poland, Germany, Israel, Austria, Czechia, Russian Federation, Denmark, Bulgaria, Hungary, France, Argentina, Brazil, Romania, Sweden
Actelion

Completed

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (MERIT-2)

Chronic Thromboembolic Pulmonary Hypertension

Poland, Ukraine, United Kingdom, China, Russian Federation, Belgium, Germany, Thailand, Hungary, France, Lithuania, Czechia, Mexico, Switzerland, Turkey
Actelion

Completed

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom

Clinical Trials Sponsored by Action, France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations